Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in children and adolescents with heterozygous familial hypercholesterolemia
NL-OMON55709Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH) (4 arms), sponsored by Sanofi. Primary endpoint: Percent change in low-density lipoprotein cholesterol from baseline to Week 24. Started Feb 2019; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NL-OMON55709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55709.